Instil Bio Inc. Cash Flow Conversion Efficiency
Instil Bio Inc. cash flow conversion efficiency. Based on the latest financial reports, Instil Bio Inc. (TIL) has a cash flow conversion efficiency ratio of -0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($110.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Instil Bio Inc. (2019–2025)
Cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. This chart illustrates how Instil Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Instil Bio Inc. share price for real-time trading data and today's change.
Instil Bio Inc. Cash Flow Conversion Ratio Explained
Instil Bio Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Instil Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Instil Bio Inc. ranked by their cash flow conversion efficiency. Also see Instil Bio Inc. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vraj Iron and Steel Ltd
NSE:VRAJ
|
0.071x |
|
LeonaBio, Inc.
NASDAQ:LONA
|
-0.424x |
|
Arrow Syndicate Public Company Limited
BK:ARROW
|
0.052x |
|
COLUMBUS ENERGY S.A. ZY 7
F:0Q8
|
0.387x |
|
Hurriyet Gazetecilik ve Matbaacilik AS
IS:HURGZ
|
-0.435x |
|
Kapuas Prima Coal Tbk PT
JK:ZINC
|
-0.015x |
|
Sungchang Hold
KO:000180
|
-0.004x |
|
Electra Battery Materials Corp
NASDAQ:ELBM
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Instil Bio Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Instil Bio Inc. from 2019 to 2025. Review financial flexibility index of Instil Bio Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $113.87 Million | $-36.62 Million | -0.322x | +2.17% |
| 2024-12-31 | $169.44 Million | $-55.70 Million | -0.329x | +9.50% |
| 2023-12-31 | $225.83 Million | $-82.03 Million | -0.363x | +26.69% |
| 2022-12-31 | $363.61 Million | $-180.16 Million | -0.495x | -125.24% |
| 2021-12-31 | $555.20 Million | $-122.14 Million | -0.220x | -117.17% |
| 2020-12-31 | $292.37 Million | $-29.62 Million | -0.101x | +84.58% |
| 2019-12-31 | $8.06 Million | $-5.29 Million | -0.657x | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.